Key result
Higher pre-PCI NRF2 levels linked to ~44% lower odds of in-hospital major cardiovascular events in STEMI.
Why the study?
The association between pre-PCI serum NRF2 levels and in-hospital MACE among STEMI patients undergoing emergency PCI, as well as the discriminatory performance of NRF2 alone and combined with conventional cardiac biomarkers, required investigation.
Does pre-PCI serum NRF2 level predict in-hospital MACE in STEMI patients undergoing emergency PCI?
Cohort (n=341)
Does pre-PCI serum NRF2 level predict in-hospital MACE in STEMI patients undergoing emergency PCI?
Lower pre-PCI serum NRF2 levels are independently associated with a higher risk of in-hospital MACE in STEMI patients undergoing emergency PCI, and adding NRF2 to cTnI and NT-proBNP improves predictive discrimination.
Answers are grounded in this paper and cite their sources.
Lower pre-PCI NRF2 may aid risk stratification in STEMI; leaves open incremental value over standard biomarkers pending validation.
To investigate the association between pre-PCI serum NRF2 levels and in-hospital MACE among STEMI patients undergoing emergency PCI, and to evaluate its discriminatory performance alone and in combination with conventional cardiac biomarkers. This prospective observational cohort study consecutively enrolled 341 STEMI patients undergoing emergency PCI from January 2023 to September 2025. Serum NRF2, NOX2, MPO, IL-6, and IL-1β were quantified using ELISA after admission and before PCI. In-hospital MACE was adjudicated from admission to discharge. Group comparisons, Spearman correlation, ROC analysis, a discharge-competing-risk analysis, and multivariable binary logistic regression were conducted. During hospitalization, 57 patients (16.7%) experienced in-hospital MACE. Patients who experienced in-hospital MACE had significantly lower serum NRF2 levels than those without events. Serum NRF2 showed significant negative correlations with cTnI, CK-MB, MPO, and IL-6. In ROC analysis, NRF2 alone demonstrated good discrimination for in-hospital MACE with an AUC of 0.760 (95% CI 0.701–0.819); the optimal cutoff was 8.8 ng/mL, yielding 80.7% sensitivity and 62.7% specificity. A combined model including NRF2, cTnI, and NT-proBNP showed a higher apparent AUC, reaching an AUC of 0.823 (95% CI 0.761–0.885), with sensitivity of 61.4% and specificity of 89.8%. Competing-risk cumulative incidence curves showed more frequent in-hospital MACE in the lower NRF2 group. In multivariable logistic regression, NRF2 remained associated with lower adjusted odds of in-hospital MACE (OR 0.556, 95% CI 0.387–0.799, p = 0.002). Lower serum NRF2 levels corresponded to higher in-hospital MACE risk among STEMI patients undergoing emergency PCI. NRF2 showed good discriminatory ability, and its combination with cTnI and NT-proBNP showed a higher apparent AUC, warranting external validation before clinical risk-stratification use.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2026) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=341). Pre-PCI serum NRF2 level vs. Conventional cardiac biomarkers (cTnI, NT-proBNP) / higher vs. lower serum NRF2 levels was evaluated on In-hospital major adverse cardiovascular events (MACE) (OR 0.556, 95% CI 0.387-0.799, p=0.002). Higher pre-PCI serum NRF2 levels were associated with lower adjusted odds of in-hospital major cardiovascular events in STEMI patients.
Synapse has enriched 10 related papers. Consider them for comparative context: